PSTV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Plus Therapeutics Inc (PSTV) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock has significant risks due to its recent reverse stock split, elevated capital risk profile, and declining financial performance. While there are potential positive catalysts in its CNSide and REYOBIQ developments, the lack of strong trading signals, neutral insider/hedge fund sentiment, and weak financials suggest holding off on investing in this stock for now.
The MACD is positive and expanding, indicating upward momentum. However, the RSI is in the neutral zone at 74.95, and moving averages are converging, showing no clear trend. The stock is trading near resistance levels (R1: 5.658, R2: 6.401), which could limit further short-term upside.
FDA approval to evaluate REYOBIQ in pediatric patients with high-grade glioma and ependymoma. Recent appointments in leadership to enhance market access and development for CNS cancers. Potential commercial upside from CNSide and REYOBIQ developments.
Recent 1-for-25 reverse stock split signals capital market strain and could pressure trading liquidity. Analysts have lowered price targets significantly, citing elevated capital risk and dilution from recent equity offerings. Declining revenue and EPS, despite improved net income.
In Q4 2025, revenue dropped by -3.19% YoY to $1,367,000. Net income improved by 46.37% YoY but remains negative at -$5,713,000. EPS dropped by -92.00% YoY to -0.04. Gross margin remained stable at 100%. Overall, financial performance shows limited growth and ongoing losses.
Analysts have mixed views but generally lowered price targets recently. Maxim reduced the price target from $37.50 to $12, citing elevated capital risk. D. Boral Capital downgraded the stock to Hold due to concerns about the reverse stock split. However, some analysts remain optimistic about the company's long-term potential in CNSide and REYOBIQ.
